This table lists all the major pharma collaborations, acquisitions and mergers during April 2013.
For an indepth analysis of these deals, read ‘Pharma deals during April 2013’
| Licensor acquired / licensee acquirer | Deal type | Product / technology | Headline ($m) |
| Conceptus/ Bayer | Acquisition | Birth control device | 1,100 |
| Actient Holdings/ Auxilium Pharmaceuticals | Acquisition | Urology specialty therapeutics company | 585 |
| Avalon/GSK | Funding | To fund up to 10 drug-discovery start-up companies over the next 3 years | 495 |
| Prolor Biotech/ Opkp Health | Acquisition | Longer-acting proprietary versions of approved therapeutic proteins | 480 |
| Isis Pharmaceuticals/ Roche | Collaboration | To develop treatments for Huntington’s disease based on Isis’ antisense oligonucleotide technology | 392 |
| Ambrx/ Astellas Pharma | Collaboration | Oncology discovery and development of novel antibody drug conjugates | 300 |
| Alchemia/ AstraZeneca | Collaboration | VAST discovery platform – multiple targets | 240+ |
| TaslyDiyi Pharma/ Tasly Pharmaceuticals | Acquisition | Maker of chemical drugs | 240 |
| Bavarian Nordic/ US Government | Award | Smallpox vaccine research | 228 |
| Bind Therapeutics/ Pfizer | Collaboration | Employ the Medicinal Nanoengineering platform to develop and commercialise Accurins | 210+ |
| Ra Pharma/ Merck & Co | Collaboration | Extreme Diversity™ platform to develop Cyclomimetic candidates for protein targets in multiple therapeutic areas | 200 |
| Forma Therapeutics/ Celgene | Collaboration | Drug-discovery platform for compounds against protein homeostasis targets | 200 |
| Bind Therapeutics/ AstraZeneca | Collaboration | Employ the Medicinal Nanoengineering platform to develop and commercialise Accurins, based on an AZ kinase inhibitor | 199 |
| Velcera/ Perrigo Company | Acquisition | Pet health products | 160 |
| Santaris Pharma/ BMS | Collaboration | Discover and develop RNA-targeted therapies based on the LNA Drug platform | 100 |
| China Animal Health Care/ Elanco (Lilly) | Part acquisition | Manufacturing, sale and distribution of animal drugs in China | 100 |
| Horizon Discovery/ AstraZeneca | Collaboration | Kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types | 75 |
| Achaogen/ Biomedical Advanced Research and Development Authority (BARDA) | Award | Phase 3 study – plazomicin to treat gram -ve bacterial infections due to Carbapenem-resistant Enterobacteriaceae | 60 |
| Pfizer/ Merck & Co* | Collaboration | Ertugliflozin as standalone and combination with Januvia and/or metformin for diabetes | 60 |
| Bracco Diagnostics/ Emergent BioSolutions | Asset purchase | Healthcare Protective Products Division | 26 |
Unless noted all transactions are for global rights
* Worldwide excluding Japan